The UK boss of the French drug manufacturer Sanofi-Aventis announced recently that the launch of the weight loss drug Acomplia in the UK had gone well and the demand for the drug was good and rising. The drug that was launched in June this year is still undergoing assessment by an organisation called NICE that was set up by the National Health Service to work out the cost effectiveness of new medicines and when that is completed the sales are likely to grow suddenly.

The verdict on the effectiveness of Acomplia is not likely to be given until 2008 but nevertheless some doctors felt that it just right for some of their patients and were ready to prescribe it. The actual data regarding the number of prescriptions given for the weight loss drug are yet to be finalised but the signs all look positive that the drug is selling well. Ukmedix was one of the first online pharmacies to offer the Acomplia drug for sale in the UK.

The way that Acomplia works is by literally turning off the brain circuits that tell you that are hungry and thus you don't go and eat. Acomplia is probably the most important new drug for Sanofi-Aventis and they estimate that if all goes well they could sell up to 3 billion dollars of the drug each year. Sanofi Aventis is at present the 3rd largest drugmaker in the UK and is busy with its Acomplia launch in Germany at present, but the drug still has not been given US approval by the FDA yet, which is worrying a few investors.

The use of Acomplia is limited to obese people ot to overweight people who have some weight related conditions like high cholesterol or who are diabetic. The drug is often touted as not only a weight loss drug but also as one that can reduce cholesterol and help people with weight related heart problems.